Naturally Splendid Enterprises Ltd. (“Naturally Splendid“, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to announce that it has entered into a Definitive Agreement with Vancouver-based Biologic Pharmamedical Research (“Biologic”) to form a joint venture for the purpose of further developing and pursuing phase 2 clinical studies for a potential COVID-19 treatment, utilizing one of Biologic’s patented technologies as a candidate.
The joint venture entity will be granted certain rights from Biologic’s patents as it relates to applications for treating COVID-19 infections. The categories to be licensed will include, but are not limited to COVID-19 applications, as well as additional respiratory indications that may arise out of the fast-tracked phase 2 clinical trial.
Previously, Naturally Splendid announced that Health Canada had issued a No Objection Letter for CavaltinibTM, the target drug, in response to the Clinical Trial Application as prepared by Biologic. The Company awaits further direction from Health Canada.
Biologic has supplied Naturally Splendid with versions of the patented technology that CavaltinibTM is based on, for almost two (2) years. In this time, the Company has gained an excellent overall understanding of the science and technologies that will be utilized in this clinical study. Naturally Splendid‘s internal R&D Scientist, Mehrab Manteghian, who holds a Doctorate of Medicine degree as well a degree in food science, has reviewed the data from the clinical studies on this technology and will be actively involved through the clinical trial process.
CavaltinibTM is an amplified variant of a current Biologic patented technology, that taken in capsule form, would greatly reduce or eliminate the need for virus infected patients to congregate in hospitals or clinics for infusions or other complex treatments. The resulting benefit of this type of capsule delivery mechanism, would make distribution of the treatment far more effective, at a fraction of the cost of treatment requiring hospitalization, which in turn could provide an extra layer of safety for front line medical staff.
We caution that this news release is not making any express or implied claims that we have the ability to eliminate the COVID-19 virus at this time.
The scientific content of this news release has been reviewed and approved by Biologic.
Naturally Splendid is pleased to announce a fully subscribed non-brokered private placement financing of up to 14,166,667 Units (each a “Unit”) at a price of $0.06 per Unit for gross proceeds of up to $850,000 (the “Offering”).
Each Unit in the non-brokered private placement consists of one common share of Naturally Splendid and one half of a common share purchase warrant (each a “Warrant”), with each Warrant entitling the holder to purchase one additional common share for a period of two years from the date of the issue at an exercise price of $0.10 per share. Naturally Splendid has the right to accelerate the expiry date of the Warrants if, at any time, the average closing price of Naturally Splendid‘s common shares is equal to or greater than $0.15 for 10 consecutive trading days. In the event of acceleration, the expiry date will be accelerated to a date that is 10 days after Naturally Splendid issues a news release announcing that it has elected to exercise this acceleration right.
Naturally Splendid may pay finders a fee in cash and/or share purchase warrants in connection with the Offering.
The securities issued under the Offering will be subject to a hold period pursuant to applicable securities laws and the rules of the TSX Venture Exchange.
The proceeds of the Offering will be directed towards preparation of the phase 2 clinical trial, retire corporate indebtedness and for general working capital purposes.
Terms of Joint Venture
The joint venture entity has been granted certain license rights from Biologic patents as it relates to applications for treating COVID-19 infections. The categories to be licensed will include, but are not be limited to, COVID-19 applications as well as additional respiratory indications that may arise out of the fast-tracked clinical trial.
Naturally Splendid will own 16% of the joint venture as well as be granted a 10% royalty on gross sales of all products and applications arising from the clinical study. Biologic will own 82% of the joint venture with 2% assigned to key personnel within Biologic at their discretion.
Biologic will also continue to run an in vitro program on tissue and cell models to further expand knowledge on pharmacological mechanisms associated with treatment of other indications such as: rheumatoid arthritis, ulcerative colitis, Crohn’s disease and/or other autoimmune or autoinflammatory diseases of which the technologies and/or products related to the findings of the clinical study will be licensed into the joint venture on similar terms.
It is expected the initial clinical trial phase directly related to COVID-19 will take 30 to 90 days with the balance of the studies over a twelve-month period intended to further expand the pharmacology.
Under the terms of the joint venture, Naturally Splendid will invest $500,000 CDN for the purpose of:
(a) preparing documentation for submission of the CTA to Health Canada.
(b) preparation of formal phase 2 clinical trials
(c) $100,000 CDN for inventory of the COVID-19 treatment product for phase 2 clinical trials;
(d) ongoing clinical trials and further research and development for a period of twelve (12) months overseen by Biologic; and
(e) preparing documentation for pre-IND application for a phase 2 COVID-19 clinical trial with the U.S. FDA.
(f) preparing and executing our own internal pilot trial
Naturally Splendid CEO Mr. Craig Goodwin states, “We continue to make progress on several fronts including significant steps towards beginning a phase 2 clinical trial for a potential COVID-19 treatment. Most unfortunately, the pandemic has continued to have widespread negative effects on the health and economies in many countries. We believe that a treatment, while vaccines are being developed, is a critical component to an overall strategy of coping with this new reality. Although a vaccine is certainly the long-term goal of the medical community, an effective treatment is very much needed. We remain optimistic that CavaltinibTM will have a positive effect to reduce the health complications arising from COVID-19 and thus potentially reducing strains on health care systems.”
For more information e-mail email@example.com or call Investor Relations at 604-673-9573
On Behalf of the Board of Directors
Mr. J. Craig Goodwin
Naturally Splendid Enterprises Ltd.
(NSP – TSX Venture; NSPDF – OTCQB; 50N – Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid‘s control including, Naturally Splendid‘s ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Copyright (c) 2020 TheNewswire – All rights reserved.
News Provided by TheNewsWire via QuoteMedia
Seattle Area Grocery Chain Metropolitan Market to Begin Carrying KOIOS and Fit Soda on March 22, 2021
Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.
Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.
Pineapple Express Delivery Partners with CannTrust to Offer Same-Day and Next-Day Delivery for estoraTM Medical Cannabis Patients in Ontario
Ensuring estoraTMpatients have seamless access to their high-quality medical cannabis products
World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announce that its subsidiary Pineapple Express Delivery Inc. (“Pineapple Express Delivery” or “PED”), a leading logistics technology company offering compliant and secure delivery of controlled substances and regulated products, has partnered with CannTrust Inc. to bring same-day and next-day delivery to estoraTM medical cannabis patients in Ontario
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.